FDA Grants Orphan Drug Status for Personalized Cancer Vaccine, BiovaxID®, Targeting Mantle Cell Lymphoma

Published July 27, 2010

FDA Grants Orphan Drug Status for Personalized Cancer Vaccine, BiovaxID®, Targeting Mantle Cell Lymphoma
TAMPA, Fla. & MINNEAPOLIS—-Biovest International, Inc. today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to BiovaxID®, Biovest’s personalized cancer vaccine, for a second lymphoma indication: mantle cell lymphoma.
Read more on Business Wire via Yahoo! Finance

AHF bans pharmaceutical sales representatives of Bristol Myers Squibb
Today AIDS Healthcare Foundation (AHF) announced that it has banned pharmaceutical sales representatives from Bristol-Myers Squibb (BMS) from calling on AHF’s medical providers and staff in its sixteen U.S. healthcare centers. The decision is based on BMS’ refusal to lower the price of its key AIDS drug Reyataz for cash-strapped AIDS Drug Assistance Programs.
Read more on News-Medical-Net